In 1983 it was shown that glucagon administered intranasally (IN) was absorbed through the nasal mucosa and increased blood glucose in healthy subjects. Shortly thereafter, it was shown that IN glucagon counteracts with hypoglycaemia in insulin-treated diabetic patients. In spite of this evidence, IN glucagon was not developed by any pharmaceutical company before 2010, when renewed interest led to intensive evaluation of a possible remedy for hypoglycaemia in insulin-treated diabetic adults and children. IN glucagon is now being developed as a needlefree device that delivers glucagon powder for treatment of severe hypoglycaemia; the ease of using this device stands in stark contrast to the difficulties encountered in use of the current intramuscular glucagon emergency kits. Studies have demonstrated the efficacy, safety and ease-of-use of this IN glucagon preparation, and suggest IN glucagon as a promising alternative to injectable glucagon for treating severe hypoglycaemia in children and adults who use insulin.
1 | BACKGROUND
| Hypoglycaemia in insulin-treated individuals with diabetes: Consequences and fears
At least 400 million individuals currently suffer from diabetes mellitus, and millions are treated with insulin to control blood glucose levels and to prevent diabetic complications. 1 Insulin can cause hypoglycaemia, a potentially severe, even life-threatening, complication that burdens insulin users each and every day. The risk is relevant to all who use insulin, whether diagnosed with type 1 diabetes mellitus (T1D) or type 2 diabetes mellitus (T2D), as well as patients with T2D who use oral agents, in particular sulphonylureas. 2, 3 Severe hypoglycaemia (SH) is defined as a circumstance that requires the assistance of a third party to treat the episode. 4 SH occurs more frequently in individuals with T1D [5] [6] [7] than in those with T2D, 3, 8 in individuals under intensive insulin treatment, 2, 9 and in the elderly, 10 with a different risk depending on regimens of insulin administration. 11 It is acknowledged that, if it was not for the barrier of hypoglycaemia, individuals with diabetes could have normal blood glucose levels and thus avoid the diabetic complications associated with hyperglycemia. 8 The fear of another episode often leads to reduced glucose control (ie, allowing blood glucose to remain higher than desired), which, in turn, increases the risk of complications. 12 Fear of hypoglycaemia can be a deterrent to patients and their families in striving for optimal metabolic control in youth with T1D, 13, 14 especially to parents of young children with T1D. 15, 16 Concerns related to hypoglycaemia are also associated with emotional distress among adults with T2D. 17 
| AVAILABLE REMEDIES
Episodes of asymptomatic hypoglycaemia, and most episodes of SH, can be effectively self-treated by ingestion of oral carbohydrates. 18 According to the Standards of Medical Care in Diabetes of the American Diabetes Association, asymptomatic hypoglycaemia and SH in a conscious individual can be treated by oral ingestion of 15 to 20 g carbohydrate, preferably as glucose tablets or an equivalent. 19 During SH, patients are unable or unwilling to take carbohydrates orally, and therefore require assistance from a third party, through administration of parenteral glucose or glucagon. 12, 20, 21 For SH in an unconscious individual in the home setting, the recommended treatment is 1 mg glucagon by intramuscular (IM) injection. For SH in an unconscious individual in the presence of professional medical assistance and intravenous (IV) access, 10 to 25 g IV dextrose is recommended. In all cases, once hypoglycaemia has been reversed, the patient should be given oral carbohydrates to prevent repeated hypoglycaemia.
| GLUCAGON
Glucagon increases plasma glucose concentrations through effects on glycogen breakdown in the liver and on glucose uptake. 22 Glucagon differs from many other peptide drugs (ie, insulin), for which a precise dose-response is critical to both safety and effectiveness. Data generated with IV or IM glucagon showed excellent dose proportionality between dose administered and glucagon pharmacokinetics (PK, maximum concentration [Cmax] and area under the curve (AUC]). The proportionality is not reflected in the pharmacodynamic (PD) response of glucose (NDA 020928, Eli Lilly), suggeting that the PD response to glucagon is saturable. Some authors, comparing IM glucagon to IV dextrose in pre-hospital settings, showed a delay in recovery from a hypoglycaemic event with glucagon, [23] [24] [25] [26] but with a steady increase in blood glucose. 24 In contrast, dextrose-treated patients seemed to have more fluctuations in blood glucose. A meta-analysis comparing IV dextrose and IM glucagon showed that the effectiveness is similar, and that the ineffectiveness of glucagon and dextrose is infrequent. 
| Problems with glucagon
Glucagon solutions are not stable, because of the propensity of glucagon to form fibrils in aqueous solution. 30 As a result, currently available glucagon emergency kits require reconstitution of lyophilized powder in a diluent immediately prior to IM injection, which falls to family mem- 36 The IN route has also become a tool to deliver PHs to the brain; animal studies suggest that insulin action in the brain is involved in the regulation of peripheral insulin sensitivity, 43 and IN insulin has been used to induce insulin sensitivity in lean and obese subjects, contrary to what happens with insulin administered peripherally, 44 and to induce immune tolerance in T1D, 45 and GLP-1 has been administered IN to modify learning and for neuroprotection. In spite of these data, a marketable IN glucagon product has not been commercialized by any pharmaceutical company. Starting in 2010, there has been renewed interest, and IN glucagon is now being developed to meet the unmet medical need for an easily-administered glucagon to treat SH. 27 Eli Lilly is now completing development of a product originally developed by Locemia.
Formulated as a dry powder, the new formulation appears to be stable under storage, 60 contains a non-toxic promoter (betacyclodextrin plus dodecylphosphocholine) and is administered using a simple, hand-held, non-toxic nasal applicator. 60, 61 IN glucagon (3 mg) has been shown to be non-inferior to IM glucagon (1 mg) 62 in treating insulin-induced hypoglycaemia in adults with T1D. A recent study compared 2-mg and 3-mg doses of IN glucagon to weight-based IM glucagon (0.5 or 1 mg) in paediatric patients (4-17 years old) with T1D. 63 This study found that both the 2-and 3-mg IN dose levels were well tolerated and resulted in a glycaemic response pattern similar to that of weight-based IM glucagon. As such, it appears that a single dose level (3 mg) can be used in children and adults with T1D, which would simplify prescription across the entire age range (≥ 4 years) of patients with T1D. Also, these data indicate that the PD response to IN glucagon is saturable, as with IM glucagon.
Nasal congestion from a common cold, with or without concomitant administration of a nasal decongestant, does not adversely affect the PK or PD of IN glucagon. 64 Another study showed that IN glucagon was well-tolerated after a single 3-mg dose, as well as after 2 doses administered 15 minutes apart (ie, 6 mg total) or 2 doses administered concurrently. 65 Beyond these studies conducted under controlled con- 
minutes)
. 33 The problems in preparing and using the current IM glucagon emergency kits stand in stark contrast to the ease of using the single-dose, needle-free IN glucagon-dispensing device used in these studies. 33 The ease of use and efficacy of IN glucagon reported in the above controlled or simulated studies has also been reported in clinical studies in which IN glucagon was dispensed to adults with T1D and caregivers of children with T1D to treat incident events of hypoglycaemia in the home and school settings. 66, 67 In these studies, IN glucagon was shown to be effective in treating moderate and severe hypoglycaemia in the real-world setting, and over 90% of caregivers reported that they were very satisfied with the ease of use of the product.
| CONCLUSION
Needle-free, ready-to-use IN glucagon is a promising alternative to injectable glucagon for caregivers, family members, friends and colleagues who may someday face the difficult task of treating SH in insulin-using children or adults with T1D. However, at present, it is not easy to foresee if this approach would be better used in place of IM in general or in special niche areas, such as children, paramedics and inpatients. Glucagon is intended for use by a third party because, by definition, treatment of SH requires the assistance of a third party.
IN glucagon might be the only drug widely prescribed for patients that is intended to be administered by someone other than the patient. 
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